Navigation Links
Former Pfizer Patent Attorneys Join Brinks Hofer Gilson & Lione
Date:9/28/2007

IP Firm Expands its Biotech and Pharma Practice

CHICAGO, Sept. 28 /PRNewswire/ -- Brinks Hofer Gilson & Lione, one of the largest intellectual property law firms in the U.S., is pleased to announce the expansion of its Biotechnology & Pharmaceutical Group with the addition of four experienced patent attorneys from Pfizer, Inc.

"We are excited to add this tremendous talent and experience to our group," said Jeffery M. Duncan, chair of the firm's BioPharma Group. "Collectively, they bring more than 35 years of in-house patent experience and perspective from world-class companies like Pfizer and Lilly. This experience and perspective will provide immense value to our biotech and pharma clients."

With these additions, the BioPharma Group at Brinks Hofer Gilson & Lione now includes 39 attorneys and six scientific advisors, including 15 individuals with advanced technical degrees (Ph.D. or M.S.). All four attorneys have joined Brinks' Ann Arbor office as counsel.

"The addition of these attorneys to the firm's Ann Arbor office expands the capabilities of this office to provide local support for clients in broad categories of leading edge technologies," said Steven L. Oberholtzer, managing partner of the Ann Arbor office of Brinks. "These seasoned professionals will most definitely enhance the firm's biotech and pharma practice representing clients globally."

The new counsels are:

Eric J. Baude, Ph.D., joins Brinks with more than eight years of experience in patent law as in-house counsel at Pfizer and at the law firm, Townsend and Townsend and Crew LLP, in San Francisco. He has prosecuted global patent portfolios and analyzed patent issues relating to pharmaceuticals, therapeutic proteins and molecular biology. Dr. Baude has provided business-focused patent counsel to R&D teams around clinical trial candidates in inflammation, bacterial infections and dermatology. He earned his J.D. from Chicago-Kent College of Law, his Ph.D. in biological chemistry from the University of Michigan and his B.S. in biochemistry from the University of Minnesota.

Cynthia M. Bott, Ph.D., joins Brinks with more than seven years of experience as in-house intellectual property counsel for Pfizer and Procter & Gamble Pharmaceuticals. In addition to patent preparation, Dr. Bott advised business managers on patent portfolio strategies and freedom to operate issues and counseled clients from early stages of discovery through clinical trials and after product launch. She has worked in the fields of pharmaceuticals, therapeutic monoclonal antibodies, peptides, peptide lipid complexes and pharmacogenomics. Prior to receiving her J.D. from the University of Cincinnati, Dr. Bott earned her Ph.D. in cellular and molecular biology from the University of Michigan and her B.S. in biochemistry from Michigan State University.

William R. Boudreaux joins Brinks with 15 years of experience in the field of intellectual property law, including roles in the pharmaceutical industry as in-house counsel for Pfizer and Eli Lilly and Company. He has focused his practice on client counseling for pharmaceutical R&D and marketing teams along the entire development timeline, including post-launch product teams and teams in early development. In addition to his counseling role, Mr. Boudreaux has extensive experience in global patent portfolio creation, legal opinions and product life-cycle planning. His experience also includes Hatch-Waxman litigation strategy and support, transactional work, appellate brief writing, and international patent procurement and enforcement. Mr. Boudreaux has a J.D. and a B.S. in biochemistry from Louisiana State University.

Michelle A. Sherwood joins Brinks with more than 12 years of legal experience and more than 15 years of experience preparing and prosecuting patents. For the past seven years at Pfizer, Ms. Sherwood has focused her practice on securing global patent portfolios for pharmaceutical companies, particularly in the area of new chemical entities. Previously, in the litigation arena, she represented pharmaceutical companies whose commercial drug patents were being infringed, as well as asserted biotechnological patents for major universities. Ms. Sherwood has a J.D. from Seton Hall University and a B.S. in chemistry from the University of Pittsburgh.

Founded in 1917, Brinks Hofer Gilson & Lione is based in Chicago with four additional offices across the country serving the intellectual property needs of clients from around the world. The firm is one of the largest IP law firms in the country, with more than 160 attorneys, scientific advisors and patent agents specializing in intellectual property litigation and all aspects of patent, trademark, copyright, trade secret, unfair competition, intellectual asset management, and technology and licensing agreements. Brinks routinely handles assignments in fields as diverse as electrical, chemical, mechanical, biotechnology, pharmaceutical, nanotechnology, Internet and computer technology, as well as in trademarks and brand names for a wide variety of products and services. For more information, visit http://www.usebrinks.com.

CONTACT:

Sydney Iglitzen

(312) 840-3163

siglitzen@usebrinks.com


'/>"/>
SOURCE Brinks Hofer Gilson & Lione
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Former smokers can be protected with vitamin A derivative
2. Reliable Help For Smokers From Nicotine Patches and Former Smokers
3. Former IMO President Shows Interest In Winning General Election
4. Former FDA Commissioner Accused in Criminal Case
5. Justice To Former Male Nurse In sex Discrimination Case
6. Residents Of Former Industrial Towns In UK Most likely To Become Obese
7. Sex Determination Test Informers to be Rewarded
8. Former Malaysian Prime Minister Suffers Heart Attack
9. Fact Sheet on Polonium-210 - The Substance That Killed Former Russian Spy
10. Former Chilean Dictator Hospitalised After Heart Attack
11. Former Chilean Dictator Recovering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... 2017 , ... Students interested in video can get a jump start on ... earn a $1,000 scholarship and have his or her video posted on the GenCure ... May 31, with the winner announced on June 9. , The competition is designed ...
(Date:1/19/2017)... PA (PRWEB) , ... January 19, 2017 , ... Allegheny ... experience of patients who seek access to the Network’s programs and services in the ... primary or specialty care appointments will be offered one for that same afternoon. ...
(Date:1/19/2017)... ... January 19, 2017 , ... For ... serves Lawrenceville, New Jersey and the surrounding area, is inaugurating a charity ... (ALS), more commonly known as Lou Gehrig's disease or motor neurone disease, is ...
(Date:1/19/2017)... ... 2017 , ... For the second consecutive year, all five ... have earned “Top Doctor” awards. Dr. Mark Leondires, Dr. Spencer Richlin, Dr. Joshua ... by their peers for the 2017 list based on their exceptional patient care ...
(Date:1/19/2017)... ... , ... The 21st Century Cures Act’s Impact on Medical Devices:, What You ... 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures          , What do ... this year? , The passage of the act means devicemakers will be scrambling to ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... , Jan 18, 2017 Research and Markets ... by Product, by End User - Global Opportunity Analysis and Industry Forecast, ... ... 2015 and is expected to reach $5,491 million by 2022, growing at ... North America was the leading regional market in global ...
(Date:1/18/2017)... SAN JOSE, Calif. , Jan. 18, 2017  Adaptive ... machines, announced today a new partnership with Hyatt Place ... guests by providing ASTI LectroFan sleep therapy machines in ... "Obviously one of the most important parts of having ... Wicks , general manager of Hyatt Place Nashville/Downtown. "We,re ...
(Date:1/18/2017)... , Jan. 18, 2017   Regenicin, Inc. ... company specializing in the development and commercialization of regenerative ... and organs, recently reported the Company,s operating results for ... As the Company described in its recent ... year of substantial accomplishments. The Company,s contract laboratory completed ...
Breaking Medicine Technology: